AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27649536 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person perspective of the virtual environment
Number of subjects: 24
Study 27649536 — intervention group
Group type: COMPARATOR
Intervention: First-person perspective of the virtual environment
Number of subjects: 24
Study 27649536 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-lifting times (0.7 seconds and 2.7 seconds)
Number of subjects: 24
Study 27649536 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-lifting angles (30° and 90°)
Number of subjects: 24
Study 24261700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-monitoring Group (TG)
Number of subjects: 62
Study 21397482 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 3189
Study 21397482 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 3189
Study 21397482 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 3189
Study 21397482 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Number of subjects: 3189
Study 21397482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Number of subjects: 3189
Study 18450876 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with laxatives
Number of subjects: 134
Study 18450876 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 134
Study 16814645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) with angiographic follow-up
Number of subjects: 1314
Study 16814645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS) with angiographic follow-up
Number of subjects: 1314
Study 16814645 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1314
Study 16814645 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1314
Study 14652636 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 30
Study 14652636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 30
Study 14652636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14652636 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Eptifibatide, Tirofiban, Placebo)
Number of subjects: 30
Study 10718687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (conference, quality improvement consultations, prevention coordinator)
Number of subjects: 4
Study 10718687 — intervention group
Group type: COMPARATOR
Intervention: Conference only group
Number of subjects: 4
Study 10718687 — intervention group
Group type: EXPERIMENTAL
Intervention: Conference and quality improvement consultations
Number of subjects: 4
Study 10718687 — intervention group
Group type: EXPERIMENTAL
Intervention: Conference and prevention coordinator
Number of subjects: 4
Study 9401745 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise of elbow flexors
Number of subjects: 0
Study 9401745 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise of elbow flexors
Number of subjects: 0
Study 1288797 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported prosthesis
Number of subjects: 700
Study 1288797 — intervention group
Group type: COMPARATOR
Intervention: Different implant designs
Number of subjects: 700
Study 1288797 — intervention group
Group type: COMPARATOR
Intervention: Different implant applications
Number of subjects: 700
Study 1288797 — intervention group
Group type: COMPARATOR
Intervention: Individual implants regarding jaw location
Number of subjects: 700
Study 1288797 — intervention group
Group type: COMPARATOR
Intervention: Implant designs
Number of subjects: 700
Study 3552853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1000 mg infusion for a maximum of 5 days)
Number of subjects: 123
Study 3552853 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (2 daily doses of 8 mg intramuscularly)
Number of subjects: 123
Study 29247636 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic-delivered screening, brief intervention and referral to treatment
Number of subjects: 660
Study 29247636 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered screening, brief intervention and referral to treatment
Number of subjects: 660
Study 29247636 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 660
Study 27514411 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment group
Number of subjects: 160
Study 27514411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment group
Number of subjects: 160
Study 27514411 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 160
Study 27514411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with paraquat poisoning
Number of subjects: 160
Study 24582019 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (images illustrating consequences of biofilm formation)
Number of subjects: 130
Study 24582019 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (biofilm disclosing tablets)
Number of subjects: 130
Study 24582019 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (combination of A and B)
Number of subjects: 130
Study 24582019 — intervention group
Group type: COMPARATOR
Intervention: Group D (control group)
Number of subjects: 130
Study 22040450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral midazolam
Number of subjects: 90
Study 22040450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg oral midazolam
Number of subjects: 90
Study 22040450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg oral midazolam
Number of subjects: 90
Study 22040450 — intervention group
Group type: COMPARATOR
Intervention: Control (0.5 mg/kg)
Number of subjects: 90
Study 20159176 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Group A) delivering 20 mcg of EE and 150 mcg of norelgestromin
Number of subjects: 40
Study 20159176 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (Group B) releasing 15 mcg of EE and 120 mcg of etonorgestrel
Number of subjects: 40
Study 20159176 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group C)
Number of subjects: 40
Study 18470901 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage-colony-stimulating factor (GM-CSF) 250 microg given before or after vaccination
Number of subjects: 32
Study 18470901 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPV) alone
Number of subjects: 32
Study 18470901 — intervention group
Group type: COMPARATOR
Intervention: No GM-CSF
Number of subjects: 32
Study 21614881 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn/soy blended flour
Number of subjects: 0
Study 21614881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use peanut butter-based lipid paste
Number of subjects: 0
Study 21614881 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no supplementary food)
Number of subjects: 0
Study 21614881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (corn/soy blended flour and peanut butter paste)
Number of subjects: 0
Study 16270719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroid budesonide (BUD)
Number of subjects: 26
Study 16270719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11864868 — intervention group
Group type: COMPARATOR
Intervention: 15 g alcohol/d
Number of subjects: 51
Study 11864868 — intervention group
Group type: COMPARATOR
Intervention: 30 g alcohol/d
Number of subjects: 51
Study 9756224 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention designed to relieve anxiety during nurse-patient consultations
Number of subjects: 0
Study 9756224 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7868786 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalysis
Number of subjects: 1215
Study 3580251 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 21336 at 200 micrograms
Number of subjects: 14
Study 3580251 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 21336 at 300 micrograms
Number of subjects: 14
Study 3580251 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 21336 at 400 micrograms
Number of subjects: 14
Study 3580251 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 21336 at 600 micrograms
Number of subjects: 14
Study 3580251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30584461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (>85% cocoa) intake for 30 days
Number of subjects: 24
Study 30584461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dark chocolate)
Number of subjects: 24
Study 27680288 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC mouth rinses for 21 days
Number of subjects: 91
Study 27680288 — intervention group
Group type: COMPARATOR
Intervention: Water (control) for 21 days
Number of subjects: 91
Study 24322483 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care clinic-based treatment with supplemental motivational interviewing (MI) phone calls
Number of subjects: 47
Study 24322483 — intervention group
Group type: COMPARATOR
Intervention: Standard of care clinic-based treatment without supplemental MI phone calls
Number of subjects: 47
Study 22319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in FGFR1
Number of subjects: 103
Study 22319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in FGF8
Number of subjects: 103
Study 22319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in PROKR2
Number of subjects: 103
Study 22319038 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genetic contribution
Number of subjects: 103
Study 20720342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) training including a group session and three e-mail sessions
Number of subjects: 261
Study 20720342 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 261
Study 20720342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) training
Number of subjects: 261
Study 18487899 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai Chi exercise plus usual care (n = 15)
Number of subjects: 30
Study 16174275 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin and metronidazole (500 mg each, three times a day for 7 days)
Number of subjects: 41
Study 12680881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (2.25 mg min‐1)
Number of subjects: 12
Study 12680881 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone (30 micro g min‐1)
Number of subjects: 12
Study 12680881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline plus Olprinone
Number of subjects: 12
Study 12680881 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 10094939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 4 years
Number of subjects: 0
Study 8732710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation at 35 mg FA.kg body wt‐1.day‐1 for 3 months
Number of subjects: 11
Study 8732710 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil (LO) supplementation at 35 mg FA.kg body wt‐1.day‐1 for 3 months
Number of subjects: 11
Study 8732710 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo for 3 months prior to active oils
Number of subjects: 11
Study 1745353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (IFN) therapy
Number of subjects: 0
Study 1745353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6979136 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold salts
Number of subjects: 10
Study 6979136 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 10
Study 6979136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (100 mg daily)
Number of subjects: 10
Study 31732558 — intervention group
Group type: EXPERIMENTAL
Intervention: FIN-RACo+IFX
Number of subjects: 99
Study 31732558 — intervention group
Group type: COMPARATOR
Intervention: FIN-RACo+PLA
Number of subjects: 99
Study 28945914 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Factor™
Number of subjects: 319
Study 28945914 — intervention group
Group type: COMPARATOR
Intervention: autograft
Number of subjects: 319
Study 26948070 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose free fatty acid (FFA) suppositories
Number of subjects: 77
Study 26948070 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose free fatty acid (FFA) suppositories
Number of subjects: 77
Study 26948070 — intervention group
Group type: COMPARATOR
Intervention: Klyx docusate sodium and sorbitol enemas (Control)
Number of subjects: 77
Study 25523533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin
Number of subjects: 504
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle-to-pulmonary artery shunt (RVPAS)
Number of subjects: 426
Study 22795436 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt (MBTS)
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe postoperative atrioventricular valve regurgitation (AVVR)
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age less than 37 weeks
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic atresia/mitral atresia
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of post‐Norwood complications
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: Census block poverty level
Number of subjects: 426
Study 22795436 — intervention group
Group type: EXPERIMENTAL
Intervention: MBTS in subjects with no or mild postoperative AVVR
Number of subjects: 426
Study 20460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception of the ankle measured by PRT on a tilting platform and OSI using the Biodex Stability System (BSS) at stable level 8 and unstable level 2.
Number of subjects: 210
Study 20460070 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT of the right leg
Number of subjects: 210
Study 20460070 — intervention group
Group type: EXPERIMENTAL
Intervention: OSI scores in left single leg stance at unstable level 2
Number of subjects: 210
Study 20460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position sense test
Number of subjects: 210
Study 18753639 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg daily)
Number of subjects: 20332
Study 18753639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20332
Study 16330605 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 18
Study 15227611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg intravenously every 24 h for 7‐14 days)
Number of subjects: 1092
Study 15227611 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotics (penicillinase‐resistant penicillins or vancomycin)
Number of subjects: 1092
Study 15227611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 1092
Study 15227611 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotics
Number of subjects: 1092
Study 15227611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin and Conventional antibiotics
Number of subjects: 1092
Study 11092405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NG) ointment applied to the skin once a day for 1 year
Number of subjects: 0
Study 11092405 — intervention group
Group type: COMPARATOR
Intervention: Estrogen replacement therapy (Premarin)
Number of subjects: 0
Study 9344303 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based treatment system
Number of subjects: 23
Study 8477914 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-enriched egg (1 egg/day)
Number of subjects: 104
Study 8477914 — intervention group
Group type: COMPARATOR
Intervention: Dietary control (low-fat diet)
Number of subjects: 104
Study 3103338 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP 10 mg/kg daily for 3 months
Number of subjects: 12
Study 3103338 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP 5 mg/kg daily for 6 months
Number of subjects: 12
Study 3103338 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP 5 mg/kg and 10 mg/kg
Number of subjects: 12
Study 3103338 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin (standard therapy)
Number of subjects: 12
Study 30455489 — intervention group
Group type: EXPERIMENTAL
Intervention: U flap technique
Number of subjects: 63
Study 30455489 — intervention group
Group type: COMPARATOR
Intervention: Conventional tympanomeatal flap technique
Number of subjects: 63
Study 26635341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT angiography (CTA)
Number of subjects: 598
Study 26635341 — intervention group
Group type: COMPARATOR
Intervention: Stress Myocardial Perfusion Tomography (SPECT)
Number of subjects: 598
Study 26635341 — intervention group
Group type: COMPARATOR
Intervention: Stress-Only (SO) SPECT
Number of subjects: 598
Study 24859851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (RTG)
Number of subjects: 30
Study 24859851 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine (RVT)
Number of subjects: 30
Study 24859851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30
Study 22877809 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 35
Study 22877809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 35
Study 22877809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20842947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (5 g/L/d)
Number of subjects: 47
Study 20842947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone (40 g/L/d)
Number of subjects: 47
Study 20842947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone with other therapy
Number of subjects: 47
Study 20842947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone with other therapy
Number of subjects: 47
Study 20842947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone without other therapy
Number of subjects: 47
Study 18789511 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 110
Study 18789511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 110
Study 18789511 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine‐N‐butylbromide
Number of subjects: 110
Study 16414520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 357
Study 16414520 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 357
Study 12576255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor muscle training during pregnancy
Number of subjects: 301
Study 12576255 — intervention group
Group type: COMPARATOR
Intervention: Customary information (Control)
Number of subjects: 301
Study 9874127 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha (2 x 10(6) IU/g) in hydrophilic gel (hydroxyethylcellulose, 1%)
Number of subjects: 60
Study 9874127 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 7752667 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and sports activity
Number of subjects: 0
Study 7752667 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 0
Study 2237968 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antithrombotic therapy (warfarin or aspirin)
Number of subjects: 0
Study 2237968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 104897 — intervention group
Group type: EXPERIMENTAL
Intervention: dimethylbiguanide + glibenclamide (n=29)
Number of subjects: 120
Study 104897 — intervention group
Group type: COMPARATOR
Intervention: placebo B + glibenclamide (n=28)
Number of subjects: 120
Study 104897 — intervention group
Group type: COMPARATOR
Intervention: placebo S + dimethylbiguanide (n=30)
Number of subjects: 120
Study 104897 — intervention group
Group type: COMPARATOR
Intervention: placebo B + S (n=33)
Number of subjects: 120
Study 104897 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphonylurea (glibenclamide)
Number of subjects: 120
Study 104897 — intervention group
Group type: EXPERIMENTAL
Intervention: biguanide administration
Number of subjects: 120
Study 104897 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 120
Study 29153637 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 289
Study 29153637 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 289
Study 29153637 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SAEs (n = 188)
Number of subjects: 289
Study 29153637 — intervention group
Group type: COMPARATOR
Intervention: Patients without SAEs
Number of subjects: 289
Study 25850030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily
Number of subjects: 102
Study 25850030 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (150 mg daily for 6 days then 75 mg daily)
Number of subjects: 102
Study 24911301 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacted by journal's editorial board members
Number of subjects: 41
Study 24911301 — intervention group
Group type: COMPARATOR
Intervention: No contact from journal's editorial board members
Number of subjects: 41
Study 22407658 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blocker
Number of subjects: 177
Study 22407658 — intervention group
Group type: EXPERIMENTAL
Intervention: behavioral migraine management
Number of subjects: 177